Response to Radioiodine Therapy for Thyrotoxicosis: Disparate Outcomes for an Indigenous Population
Table 4
Factors influencing radioactive iodine outcome.
Success
Failure
Age
175
55.0 (52.8, 57.2)
48
49.1 (45.3, 52.9)
0.0117
Gender
F
175
148 (84.6%)
48
36 (75.0%)
0.122
M
27 (15.4%)
12 (25.0%)
Diagnosis
GD
175
109 (62.3%)
48
33 (68.8%)
0.369
TMNG
60 (34.3%)
15 (31.2%)
STA
6 (3.4%)
0 (0%)
Ethnicity
NMāori
167
121 (72.5%)
46
21 (45.6%)
0.001
Māori
46 (27.5%)
25 (54.4%)
Weight (kg)
161
74.5 (52.2, 118)
47
75.2 (53.8, 118.1)
0.6674
Ophthalmopathy
Nil
106
81 (76.4%)
34
22 (64.7%)
Mild
18 (17.0%)
8 (23.5%)
Mod.
5 (4.7%)
2 (5.9%)
Sev.
2 (1.9%)
2 (5.9%)
0.461
T4 at presentation
164
27.3 (12.0, 60.1)
46
39.8 (16.9, 68.0)
0.0003
Pretreatment ATD
175
147 (84.0%)
48
47 (97.9%)
0.011
Length of pretreatment (wks)
146
44 (13, 335)
47
57 (13, 556)
0.2533
Posttreatment ATD
145
49 (33.79%)
47
25 (53.19%)
0.018
Length of follow-up (wks)
175
875 (419, 1466)
48
961 (456, 1483)
0.1148
ATD: antithyroid medication; F: female; M: male; GD: Graves’s disease; TMNG: toxic multinodular goitre; STA: solitary toxic adenoma; NMāori: non-Māori; Mod.: moderate eye disease; Sev.: severe eye disease. Continuous variables are expressed as mean (95% confidence intervals) or median (5th, 95th percentile) according to their distribution. Categorical variables are expressed as number (percentage).
